ENTRESTO

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Spain, Tunisia, UK.

Active ingredients

The drug ENTRESTO contains a combination of these active pharmaceutical ingredients (APIs):

1	Sacubitril UNII 17ERJ0MKGI - SACUBITRIL
	Sacubitril is a prodrug and its active metabolite, LBQ657, inhibits neprilysin (neutral endopeptidase; NEP). The complementary cardiovascular benefits in heart failure patients are attributed to the enhancement of peptides that are degraded by neprilysin, such as natriuretic peptides (NP), by LBQ657.
	Read more about Sacubitril
2	Valsartan UNII 80M03YXJ7I - VALSARTAN
	Valsartan is an orally active, potent, and specific angiotensin II (Ang II) receptor antagonist. It acts selectively on the AT1-receptor subtype, which is responsible for the known actions of angiotensin II.
	Read more about Valsartan

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ENTRESTO Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C09DX04	Valsartan and sacubitril	C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09D Angiotensin II antagonists, combinations → C09DX Angiotensin II antagonists, other combinations
Discover more medicines within C09DX04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11122J, 11123K, 11131W
BR	Câmara de Regulação do Mercado de Medicamentos	526517080090401, 526517080090501, 526517080090601, 526517080090701, 526517080090801
CA	Health Products and Food Branch	02446928, 02446936, 02446944
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	4960-MEE-0220, 4961-MEE-0220, 4962-MEE-0220
EE	Ravimiamet	1704147, 1704158, 1704169, 1704170, 1704181, 1704192, 1736805, 1736816, 1736827, 1736838, 1736849, 1736850, 1736861, 1736872, 1736883, 1736894, 1771185
ES	Centro de información online de medicamentos de la AEMPS	1151058001, 1151058003, 1151058006
FI	Lääkealan turvallisuus- ja kehittämiskeskus	104675, 409547, 448897, 466739, 470817, 550845, 577135, 585287
FR	Base de données publique des médicaments	61816438, 65122144, 65849001
GB	Medicines & Healthcare Products Regulatory Agency	311365, 311369, 311378, 311381
HK	Department of Health Drug Office	64630, 64631, 64632, 65170, 65171, 65172, 65318, 65319, 65320
IE	Health Products Regulatory Authority	32412, 32413, 32414, 32415
IL	מִשְׂרַד הַבְּרִיאוּת	7789, 7791, 7792
JP	医薬品医療機器総合機構	2190041F1027, 2190041F2023, 2190041F3020
LT	Valstybinė vaistų kontrolės tarnyba	1079112, 1079113, 1079114, 1079115, 1079116, 1079117, 1079118, 1079858, 1079859, 1079860, 1079861, 1079862, 1079863, 1079864, 1079865, 1079866, 1084357, 1089047, 1089048, 1089049, 1089050, 1089051
NL	Z-Index G-Standaard, PRK	132071, 132098, 132101
NZ	Medicines and Medical Devices Safety Authority	18156, 18157, 18158
PL	Rejestru Produktów Leczniczych	100309013, 100357087, 100357093
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W64479001, W64480001, W64481001
SG	Health Sciences Authority	14947P, 14948P, 14949P
TN	Direction de la Pharmacie et du Médicament	10283371, 10283372, 10283373
US	FDA, National Drug Code	0078-0659, 0078-0696, 0078-0777
ZA	Health Products Regulatory Authority	50/7.6/1016, 50/7.6/1017, 50/7.6/1018